CurveBeam AI (ASX:CVB) does not expect any material impact from the Trump administration's tariffs, saying most of the components it uses come from US partners, according to a Tuesday filing with the Australian bourse.
The company, which makes point-of-care specialized medical imaging equipment, conducts its manufacturing activities within the US. The majority of components derived from its US partners represent around 75% of the cost of goods, per the filing.
"Based on an initial risk assessment, the company does not expect material adverse effects from the tariff changes," CurveBeam said in the filing.
The company's shares were up 6% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。